52 completed, 28 active not recruiting, 22 recruiting, 19 terminated. 133 Phase 1, 38 Phase 2.
Follow olaparib: new trials by email Literature Review of olaparib trials Research Report on olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib - Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 60 | 2026-07-14 | 2026-09-10 |
| Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg) - Cancer, Ovarian Cancer | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 40 | 2026-04-22 | 2026-05-08 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
| Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss MRTX1719, Olaparib - Advanced Cancer, Solid Tumor | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-02-12 | 2026-08-12 |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Cirtuvivint, Olaparib - Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Recruiting | University of Colorado, Denver | 50 | 2025-12-08 | 2026-07-24 |
| Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Withdrawn | Peter MacCallum Cancer Centre, Australia | 2025-11-01 | 2026-10-30 | |
| A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Olaparib 150 MG - Ovarian Cancer | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 24 | 2025-06-17 | 2025-07-16 |
| The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer Olaparib - Ovarian Cancer, Epithelial Cancer | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 55 | 2025-05-01 | 2026-03-10 |
| Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors SIM0508 Tablets, SIM0508 in combination with olaparib - Advanced Solid Tumors | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 130 | 2024-12-06 | 2025-01-07 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily - Advanced Solid Tumor | Phase 1 | Terminated | Repare Therapeutics | 26 | 2024-09-17 | 2026-01-16 |
| EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors EIS-12656, Olaparib, Trastuzumab deruxtecan - Advanced Solid Tumor, Homologous Recombination Deficiency | Phase 1 / Phase 2 | Recruiting | Eisbach Bio GmbH | 144 | 2024-09-09 | 2024-09-19 |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors MOMA-313, Olaparib - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | MOMA Therapeutics | 220 | 2024-08-13 | 2026-07-23 |
| Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer Axatilimab, Olaparib - Breast Cancer, PALB2-Mutated Breast Carcinoma | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 20 | 2024-08-13 | 2026-09-02 |
| Estradiol Plus Olaparib for Breast Cancer (PHOEBE) Olaparib, 17b-estradiol - Metastatic Breast Cancer | Phase 1 | Recruiting | Mary D Chamberlin | 6 | 2024-07-15 | 2025-11-20 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors XL309, Olaparib - Advanced Solid Tumor | Phase 1 | Recruiting | Exelixis | 429 | 2024-04-03 | 2025-09-05 |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Patritumab deruxtecan, Olaparib - Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 152 | 2024-03-21 | 2026-09-04 |
Showing 20 of 133. Sign in to see all of them.
Breast Neoplasms (31) · Ovarian Neoplasms (26) · Neoplasm Metastasis (14) · Prostatic Neoplasms (13) · Triple Negative Breast Neoplasms (12) · Neoplasms (10) · Fallopian Tube Neoplasms (9) · Pancreatic Neoplasms (9) · Small Cell Lung Carcinoma (7) · Endometrial Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Recurrence (5) · Squamous Cell Carcinoma of Head and Neck (5) · Neuroendocrine Tumors (4)
AstraZeneca (26) · National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (8) · The Netherlands Cancer Institute (5) · Dana-Farber Cancer Institute (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Memorial Sloan Kettering Cancer Center (3) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · OHSU Knight Cancer Institute (2) · Peter MacCallum Cancer Centre, Australia (2) · Repare Therapeutics (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University College, London (2) · University of Colorado, Denver (2)
United States (77) · United Kingdom (29) · France (16) · Netherlands (15) · Spain (13) · Canada (9) · South Korea (8) · Australia (7) · Belgium (7) · China (5) · Denmark (5) · Italy (5) · Japan (4) · Switzerland (4) · Germany (2)
Jane Robertson, BSc, MBCHB, MD (6) · Anitra Fielding (2) · Filipa Lynce, MD (2) · James Carmichael, BSc MBChB MD FRCP (2) · Marcel Verheij, MD, PhD (2) · Timothy A Yap (2) · Abraham Wu, MD (1) · Adam Crystal, MD, PhD (1) · Alastair Greystoke, MB ChB, MSc, PhD (1) · Alberto A Chiappori, MD (1) · Andres Poveda, MD (1) · Andrew Jackson, Dr (1) · Anish Thomas, M.D. (1) · Anna Farago, MD, PhD (1)
PMID 31500595, PMID 32379297, PMID 34904813, PMID 38885312, PMID 22248721, PMID 23922302, PMID 26961146, PMID 40607251, PMID 42820295, PMID 19553641, PMID 22145984, PMID 23524863, PMID 23810467, PMID 24063698, PMID 25025963, PMID 25218906, PMID 25573533, PMID 26242220, PMID 27075016, PMID 27169564, PMID 27323902, PMID 28454122, PMID 30217671, PMID 30324586, PMID 30514390, PMID 30700568, PMID 30880072, PMID 31345267, PMID 31534013, PMID 31538815, PMID 31637669, PMID 31667659, PMID 32164626, PMID 32203306, PMID 32532747, PMID 32571298, PMID 32771088, PMID 32827353, PMID 32897402, PMID 32971187, PMID 33070053, PMID 33892407, PMID 33909232, PMID 33927108, PMID 33954826, PMID 34347542, PMID 34543871, PMID 34562230, PMID 34829796, PMID 34965890
2015 (5), 2023 (5), 2014 (3), 2016 (3), UM1CA186689 (3), UM1CA186709 (3), 2008 (2), UM1CA186688 (2), 2005 (1), 2018 (1), 2019 (1), N01CM00071 (1), P30CA006516 (1), P30CA046592 (1), P50CA083639 (1)